Treeline Biosciences goes public via reverse merger with Standard BioTools, gaining a $900M cash runway through 2029 for its three Phase 1 oncology programs.
Treeline cofounders Josh Bilenker (left) and Jeff Engelman
June 8, 2026 11:16 AM EDT
Treeline to go public via reverse merger with Standard BioTools
Treeline Biosciences has shared plans to debut on public markets through a reverse merger with Standard BioTools in a move that should give the company …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Stealthy startup Treeline plans a reverse merger
TransCode Therapeutics to Host R&D Webcast on June 18, 2026
Meridian Bioscience and 4bases Announce Collaboration to Enable Rapid, Globally Scalable Next-Generation Sequencing Workflows
Trulieve Announces Uplist to NYSE
Join Calidi Biotherapeutics' Exclusive Live Investor Webinar and Q&A Session on June 9
As China biotech crackdown calls reverberate in Washington, the pushback gets louder, too
Parabilis Medicines 33.5M share IPO priced at $20.00
Led by former Loxo Oncology CEO Josh Bilenker, the startup now has a trio of cancer drugs in early-stage testing and more…
New guidance for gene therapy developers, Lilly's deal for kidney drugs, and more biotech news from The Readout
As large biopharma companies have increasingly turned to China for novel biotech innovation, political calls in the U.S. to block…
Latus Bio raised $42 million as it prepares to seek FDA approval to start a clinical trial for its gene therapy for Huntington's…
TransCode Therapeutics to Host R&D Webcast on June 18, 2026
bitBiome Closes Oversubscribed Seed Extension Round
